 CAMBRIDGE, Mass., March 30, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation for one of the companys lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer. 